XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS DESCRIPTION (Narrative) (Details) - USD ($)
3 Months Ended 12 Months Ended
Apr. 02, 2021
Jun. 26, 2020
Mar. 26, 2020
Sep. 07, 2018
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Apr. 30, 2020
Apr. 13, 2020
Business Acquisition [Line Items]                      
Oncology test reporting time           1 day          
Net loss         $ 1,500,000            
Working deficiency         300,000            
Net cash used in operating activities         (1,289,000)     $ (1,589,000)      
Proceeds from issuance of common stock         $ 1,260,000     $ 1,350,000      
Proceeds from long-term debt                 $ 800,000    
Common stock, par value         $ 0.01       $ 0.01    
Term of test reporting time for patients         1 day            
Maximum                      
Business Acquisition [Line Items]                      
Oncology test reporting time             10 days        
Term of test reporting time for patients         10 days            
Minimum                      
Business Acquisition [Line Items]                      
Oncology test reporting time             7 days        
Term of test reporting time for patients         7 days            
Sales Agreement with Alliance Global Partners                      
Business Acquisition [Line Items]                      
Maximum aggregate initial offering price                     $ 50,000,000
Lincoln Park [Member]                      
Business Acquisition [Line Items]                      
Value of shares issued     $ 10,000,000 $ 10,000,000              
Shares sold in offering (in shares)     4,980,000         930,012      
Proceeds from issuance of common stock               $ 1,300,000      
Equity purchase agreement value remaining available     $ 1,200,000                
Sale of common stock   4,500,000                  
LP 2020 Purchase Agreement [Member]                      
Business Acquisition [Line Items]                      
Proceeds from issuance of common stock     $ 8,800,000                
Subsequent Events | Sales Agreement with Alliance Global Partners                      
Business Acquisition [Line Items]                      
Proceeds from issuance of common stock $ 15,400,000                    
Common stock, par value $ 0.01                    
Sale of common stock 4,501,000                    
Additional shares available for future sales $ 6,600,000                    
Subsequent Events | Sales Agreement with Alliance Global Partners | Maximum                      
Business Acquisition [Line Items]                      
Proceeds from issuance of common stock $ 22,000,000                    
Joint Venture [Member]                      
Business Acquisition [Line Items]                      
Percentage of interest in joint venture                   49.00%  
Joint Venture [Member] | Poplar Put Right [Member] | Scenario, Plan [Member]                      
Business Acquisition [Line Items]                      
Percentage of interest in joint venture                   100.00%  
Price per share                   $ 1.00  
Purchase price                   $ 51  
Joint Venture [Member] | Popular Healthcare PLLC [Member]                      
Business Acquisition [Line Items]                      
Percentage of interest in joint venture                   51.00%